Gennova Biopharmaceuticals gets DCGI nod for mRNA-based Covid booster vaccine
GEMCOVAC-OM is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant.
GEMCOVAC-OM is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant.
The company divested its pharma portfolio in India to fund a new thrust in vaccines against pandemic outbreaks.
About 97% of eligible beneficiaries have already received at least one dose of Covid-19 vaccine and around 90% have received both the doses.
While the initial rollout will be for supplies to the government vaccination programme, commercial open sales may begin early 2023, says Adar Poonawalla.
The funding seeks to establish preclinical and clinical proof of concept for a vaccine designed to provide protection against all known SARS-CoV-2 variants.
While 65.65 crore Indians have taken both the doses, first dose has been taken by 91.08 crore people.
The company’s effort to find a new method to treat Covid-19 patients comes at a time when India is in the midst of a third wave of infection.
Poonawalla says the biggest learning from the pandemic has been the realisation that one should not make forward looking predictions, as things have been changing fast with Covid-19
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
The quartet of vaccine-makers from the western world are ascertaining the need to tweak their vaccines for the Omicron, whereas WHO states it is too early to comment on its virulence.